Written by Peter Liu
Spoon Feed
Prostate MRI may be a reasonable next step for patients with positive PSA screening for prostate cancer.
Synopsis
This Swedish study evaluated the consequences of using MRI-targeted biopsies for prostate cancer screening in men aged 50–60, rather than systemic, random core biopsies, following elevated prostate-specific antigen (PSA) levels. Over 3.9 years of median follow-up, MRI-targeted biopsy significantly reduced diagnoses of clinically insignificant prostate cancer by 57% compared to systematic biopsy while maintaining similar detection rates for clinically significant cancers. Advanced or high-risk cancer detection rates were low and comparable across groups. The findings support the use of MRI-based screening strategies to reduce unnecessary biopsies and overdiagnosis without a clear compromise in the detection of significant cancers. (AI-generated)
Prostate cancer scan before you sample?
Prostate cancer counseling for general physicians remains challenging due to uncertainties surrounding screening benefits and risks. While prostate cancer is the second most common cancer diagnosis and cause of cancer death in U.S. men, careless screening may lead to unnecessary biopsies and overdiagnosis of indolent cancers with little health impact. Notably, there is no conclusive evidence that PSA screening reduces mortality. This study proposes incorporating prostate MRI after a positive PSA screen, particularly for PSA levels between 3-10 ng/mL. Biopsies could be avoided in the absence of suspicious MRI lesions or targeted to specific lesions rather than performing random sampling of the prostate. This approach could reduce low-risk cancer diagnoses and biopsy-related risks while maintaining detection rates for clinically significant cancers. However, the generalizability of these findings is limited by underrepresentation of Black, Asian, and Hispanic patients in the Swedish study. Ultimately, most patients that decide on PSA screening are referred to a prostate cancer specialist for decisions about MRI versus biopsy. Still, understanding the possible role that prostate MRI could play in tailoring patients’ prostate evaluation to their individual situations could help us to more accurately describe the complicated process that follows PSA screening, and potentially help advocate for a thoughtful approach post-PSA.
Source
Results after Four Years of Screening for Prostate Cancer with PSA and MRI. N Engl J Med. 2024 Sep 26;391(12):1083-1095. doi: 10.1056/NEJMoa2406050. PMID: 39321360
